RI2 Stock Overview
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rigel Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.60 |
| 52 Week High | US$14.76 |
| 52 Week Low | US$6.68 |
| Beta | 0.93 |
| 11 Month Change | 25.86% |
| 3 Month Change | 89.12% |
| 1 Year Change | 43.00% |
| 33 Year Change | -51.37% |
| 5 Year Change | -10.43% |
| Change since IPO | -81.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| RI2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.7% | 1.0% | 1.5% |
| 1Y | 43.0% | -15.4% | 12.6% |
Return vs Industry: RI2 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: RI2 exceeded the German Market which returned 12.6% over the past year.
Price Volatility
| RI2 volatility | |
|---|---|
| RI2 Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RI2's share price has been volatile over the past 3 months.
Volatility Over Time: RI2's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 147 | Raul Rodriguez | www.rigel.com |
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company.
Rigel Pharmaceuticals, Inc. Fundamentals Summary
| RI2 fundamental statistics | |
|---|---|
| Market cap | €252.19m |
| Earnings (TTM) | -€12.75m |
| Revenue (TTM) | €116.63m |
2.2x
P/S Ratio-19.8x
P/E RatioIs RI2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RI2 income statement (TTM) | |
|---|---|
| Revenue | US$130.20m |
| Cost of Revenue | US$31.12m |
| Gross Profit | US$99.08m |
| Other Expenses | US$113.32m |
| Earnings | -US$14.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 76.10% |
| Net Profit Margin | -10.93% |
| Debt/Equity Ratio | -333.2% |
How did RI2 perform over the long term?
See historical performance and comparison